Availability of miltefosine for the treatment of kala-azar in India.
作者信息
Sundar Shyam, Murray Henry W
机构信息
Institute of Medical Sciences, Banaras Hindu University, 6 SK Gupta Nagar, Lanka, Varanasi 221-005, India.
出版信息
Bull World Health Organ. 2005 May;83(5):394-5. Epub 2005 Jun 24.
Abstract
摘要
相似文献
1
Availability of miltefosine for the treatment of kala-azar in India.
Bull World Health Organ. 2005 May;83(5):394-5. Epub 2005 Jun 24.
2
Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
J Assoc Physicians India. 2003 Jul;51:686-90.
3
Oral miltefosine in the treatment of kala-azar.
Natl Med J India. 2000 Jul-Aug;13(4):202-3.
4
Treatment of leishmaniasis with miltefosine: 2008 status.
Expert Opin Drug Metab Toxicol. 2008 Sep;4(9):1209-16. doi: 10.1517/17425255.4.9.1209.
5
Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Am J Trop Med Hyg. 2009 Mar;80(3):336-8.
6
Oral miltefosine in post-kala-azar dermal leishmaniasis--experience in three cases.
Int J Dermatol. 2010 May;49(5):565-9. doi: 10.1111/j.1365-4632.2010.04326.x.
7
Breakthrough in the management of visceral leishmaniasis.
J Assoc Physicians India. 2003 Jul;51:649-51.
8
Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
Clin Exp Dermatol. 2008 Jan;33(1):103-5. doi: 10.1111/j.1365-2230.2007.02547.x. Epub 2007 Nov 2.
9
Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
Future Microbiol. 2010 Sep;5(9):1301-3. doi: 10.2217/fmb.10.92.
10
Kala-azar--progress against a neglected disease.
N Engl J Med. 2002 Nov 28;347(22):1793-4. doi: 10.1056/NEJMe020133.
引用本文的文献
1
Finishing the task of eliminating neglected tropical diseases (NTDs) in WHO South-East Asia Region: promises kept, challenges, and the way forward.
Lancet Reg Health Southeast Asia. 2023 Oct 29;18:100302. doi: 10.1016/j.lansea.2023.100302. eCollection 2023 Nov.
2
TCP1γ Subunit Is Indispensable for Growth and Infectivity of Leishmania donovani.
Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.00669-20.
3
Impact of sequelae of visceral leishmaniasis and their contribution to ongoing transmission of Leishmania donovani.
Pathog Dis. 2019 Aug 1;77(6). doi: 10.1093/femspd/ftz057.
4
Enhancement Effect of Shark Cartilage Extract on Treatment of with Artemisinin and Glucantime and Evaluation of killing Factors and Apoptosis Condition.
Iran J Pharm Res. 2019 Spring;18(2):887-902. doi: 10.22037/ijpr.2019.1100656.
5
Evaluation of synergistic therapeutic effect of shark cartilage extract with artemisinin and glucantime on visceral leishmaniasis in BALB/c mice.
Iran J Basic Med Sci. 2019 Feb;22(2):146-153. doi: 10.22038/ijbms.2018.31124.7504.
6
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.
Clin Microbiol Rev. 2018 Aug 29;31(4). doi: 10.1128/CMR.00048-18. Print 2018 Oct.
7
Antileishmanial Activity of Amphotericin B-loaded-PLGA Nanoparticles: An Overview.
Materials (Basel). 2018 Jul 9;11(7):1167. doi: 10.3390/ma11071167.
8
Why miltefosine-a life-saving drug for leishmaniasis-is unavailable to people who need it the most.
BMJ Glob Health. 2018 May 3;3(3):e000709. doi: 10.1136/bmjgh-2018-000709. eCollection 2018.
9
Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Parasit Vectors. 2017 Jan 31;10(1):49. doi: 10.1186/s13071-017-1969-z.
10
Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01169-16. Print 2017 Mar.
Zotero 插件